참고문헌
- Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/ AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41. https://doi.org/10.1016/j.jacc.2009.10.015
- Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013;62:496-504. https://doi.org/10.1016/j.jacc.2013.05.022
- Min GS, Lee JH, Park JH, et al. Long-term safety and efficacy of sirolimus- and Paclitaxel-eluting stents in patients with acute myocardial infarction: four-year observational study. Korean Circ J 2012;42:266-73. https://doi.org/10.4070/kcj.2012.42.4.266
- Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-91. https://doi.org/10.1161/CIRCULATIONAHA.112.097014
- Jiménez-Quevedo P, Hernando L, Gómez-Hospital JA, et al. Sirolimuseluting stent versus bare metal stent in diabetic patients: the final fiveyear follow-up of the DIABETES trial. EuroIntervention 2013;9:328-35. https://doi.org/10.4244/EIJV9I3A54
- De Luca G, Dirksen MT, Spaulding C, et al. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol 2013;111:1295-304. https://doi.org/10.1016/j.amjcard.2013.01.281
- Souza CF, El Mouallem AM, Brito Junior FS, et al. Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STEnt IN patients with coronary artery disease) Registry. Einstein (Sao Paulo) 2013;11:350-6. https://doi.org/10.1590/S1679-45082013000300015
- Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L. Final 5-year outcomes from the endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. JACC Cardiovasc Interv 2013;6: 504-12. https://doi.org/10.1016/j.jcin.2012.12.125
- Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90. https://doi.org/10.1016/S0140-6736(12)61223-9
- Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74. https://doi.org/10.1016/0735-1097(92)90476-4
- Jonas M, Edelman ER, Groothuis A, Baker AB, Seifert P, Rogers C. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res 2005;97:725-33. https://doi.org/10.1161/01.RES.0000183730.52908.C6
- Schwartz RS, Edelman E, Virmani R, et al. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 2008;1:143-53. https://doi.org/10.1161/CIRCINTERVENTIONS.108.789974
- Kolodgie FD, John M, Khurana C, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002;106:1195-8. https://doi.org/10.1161/01.CIR.0000032141.31476.15
- Onuma Y, Miquel-Hebert K, Serruys PW; SPIRIT II Investigators. Fiveyear long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. EuroIntervention 2013;8:1047-51. https://doi.org/10.4244/EIJV8I9A161
- Yamasaki M, Tsujino I, Lima-Filho MO, et al. Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial. Euro- Intervention 2012;8:724-31.
- Vardi M, Burke DA, Bangalore S, et al. Long term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: Pooled 5-year results from the ENDEAVOR III and IV trials. Catheter Cardiovasc Interv 2013. [Epub ahead of print]
- Kim SJ, Lee H, Cho JM, et al. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study. Coron Artery Dis 2013;24:431-9. https://doi.org/10.1097/MCA.0b013e328362b2e7
- Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE- Korea registries. J Am Coll Cardiol 2013;61:536-44. https://doi.org/10.1016/j.jacc.2012.11.015
- Hannan EL, Zhong Y, Wu C, et al. Everolimus-eluting stents and zotarolimus- eluting stents for percutaneous coronary interventions: twoyear outcomes in New York State. Catheter Cardiovasc Interv 2013;81: 1097-105. https://doi.org/10.1002/ccd.24512
- Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60. https://doi.org/10.1016/S0140-6736(12)61852-2
- Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus- eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013;62: 181-90. https://doi.org/10.1016/j.jacc.2013.04.045
- Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-22. https://doi.org/10.1093/eurheartj/ehs086
- Park KH, Jeong MH, Kim JM, et al. The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. Int J Cardiol 2013;168:1853-8. https://doi.org/10.1016/j.ijcard.2012.12.070
- Räber L, Kelbæk H, Ostoijc M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87. https://doi.org/10.1001/jama.2012.10065
- Vorpahl M, Yazdani SK, Nakano M, et al. Pathobiology of stent thrombosis after drug-eluting stent implantation. Curr Pharm Des 2010;16: 4064-71. https://doi.org/10.2174/138161210794454879
- Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol 2009;57:567-84.
- Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus- eluting cypher stent in a porcine model. Circ Cardiovasc Interv 2010;3:174-83. https://doi.org/10.1161/CIRCINTERVENTIONS.109.877522
- Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 2006;3:731-41. https://doi.org/10.1586/17434440.3.6.731
- Ostojic M, Sagic D, Jung R, et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv 2008;72: 901-8. https://doi.org/10.1002/ccd.21775
- Malik N, Gunn J, Holt CM, et al. Intravascular stents: a new technique for tissue processing for histology, immunohistochemistry, and transmission electron microscopy. Heart 1998;80:509-16. https://doi.org/10.1136/hrt.80.5.509
피인용 문헌
- Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer : NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolim vol.8, pp.10, 2015, https://doi.org/10.1161/circinterventions.115.002817
- Clinical Outcome Comparison of Everolimus- and Biolimus-eluting Stents in Patients with Acute Myocardial Infarction vol.89, pp.4, 2013, https://doi.org/10.3904/kjm.2015.89.4.418
- Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravasc vol.37, pp.45, 2013, https://doi.org/10.1093/eurheartj/ehw389
- Outcomes of Acute Myocardial Infarction Patients Implanted With Biodegradable Polymer Biolimus-Eluting Stents Versus New-Generation Durable Polymer Drug-Eluting Stents: A Retrospective Analysis vol.68, pp.8, 2017, https://doi.org/10.1177/0003319716679339
- Sirolimus coating on heparinized stents prevents restenosis and thrombosis vol.31, pp.10, 2013, https://doi.org/10.1177/0885328217706222